CNBX Pharmaceuticals, Inc. is a clinical stage company, which engages in the discovery, development, and commercialization of cannabinoid-based products and technologies for the treatment of cancer. The company is headquartered in Bethesda, Maryland and currently employs 2 full-time employees. The company went IPO on 2007-07-02. The firm's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The firm indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.
Follow-Up Questions
Who is the CEO of CNBX Pharmaceuticals Inc?
Mr. Eyal Barad is the Chief Executive Officer of CNBX Pharmaceuticals Inc, joining the firm since 2017.
What is the price performance of CNBX stock?
The current price of CNBX is $0.0003, it has decreased 0% in the last trading day.
What are the primary business themes or industries for CNBX Pharmaceuticals Inc?
CNBX Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is CNBX Pharmaceuticals Inc market cap?
CNBX Pharmaceuticals Inc's current market cap is $27752.999999999996
